Payment overview · 2025
General Payments
$190.38
6 reported records · 6 companies
Healthcare provider profile · identity verified
Zafar U Khalid, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MERRILLVILLE, IN · NPI 1689657975
Verified facts
What the public records show
CMS Open Payments records show Zafar U Khalid, MD received $190.38 in general payments during 2025 across 6 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $50.08 | 26.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $49.58 | 26.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.43 | 14.9% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $26.27 | 13.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.23 | 10.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.79 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $190.38 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $50.08 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $49.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 293 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 61 |
| Losartan Potassium | Losartan Potassium | 171 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 38 |
| Gabapentin | Gabapentin | 145 | 41 |
| Metformin Hcl | Metformin Hcl | 127 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 36 |
| Furosemide | Furosemide | 120 | 32 |
| Potassium Chloride | Potassium Chloride | 120 | 31 |
| Alprazolam | Alprazolam | 106 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 31 |
| Meloxicam | Meloxicam | 100 | 36 |
| Lisinopril | Lisinopril | 98 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 26 |
| Glipizide | Glipizide | 84 | 21 |
| Omeprazole | Omeprazole | 79 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 19 |
| Eliquis | Apixaban | 61 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 20 |
| Metformin Hcl Er | Metformin Hcl | 57 | 18 |
| Warfarin Sodium | Warfarin Sodium | 55 | 14 |
| Allopurinol | Allopurinol | 52 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 13 |
| Methylprednisolone | Methylprednisolone | 49 | 42 |
| Montelukast Sodium | Montelukast Sodium | 48 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 14 |
| Ramipril | Ramipril | 40 | 11 |
| Azithromycin | Azithromycin | 39 | 35 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | 11 |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Klor-Con M10 | Potassium Chloride | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 12 |
| Prednisone | Prednisone | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $190.38 · 6 records | SANOFI-AVENTIS U.S. LLC | AIRSUPRA, KRYSTEXXA, REZDIFFRA, TZIELD, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error